Biomarker discordance: why it occurs and why it is important.

摘要: Although the analysis of hormone receptors and HER-2/neu has usually been performed on primary tumors only, a growing body evidence suggests that substantial discordance exists between metastatic disease for estrogen (30-40%) (10-30%). This may reflect alterations in pathologic assessment techniques, changes breast cancer, differences within heterogenous tumor, or effect treatment. The etiology is poorly understood frequently tumor heterogeneity along with lack standardized preanalytic analytic variables. Standardization diagnostic variables can improve reproducibility. Because emergence targeted hormonal therapies, biomarkers assume pivotal role treatment decisions. loss sensitivity to hormones suggest resistance; whereas, acquisition provides potential new targets which overall patient outcomes.